September 29, 2011 — A series of media reports in the past few weeks have detailed mounting problems at Dendreon, the Seattle, Washington–based maker of the immunotherapy sipuleucel-T (Provenge), ...

A new survey of cancer doctors published in a research note from investment bank R.W. Baird provides some more reasons for investors to worry about Dendreon and its prostate cancer treatment Provenge, ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

NEW YORK (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators and ...

November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...

One of the first big stories I wrote about at Forbes was the controversy over embryonic stem cells that raged in 2000 and 2001 and resulted in a major compromise announced by President Bush ten years ...

Two cancer doctors have received threatening e-mails in recent weeks because of their opposition to Provenge, an experimental prostate-cancer drug developed by Seattle-based Dendreon. The doctors, ...

-FDA Approval of Additional 36 Workstations in New Jersey Manufacturing Facility Provides Increased Availability of First-in-Class Prostate Cancer Immunotherapy PROVENGE- SEATTLE, March 10, 2011 ...

Shares of Dendreon surged Thursday after the company said sales of its prostate-cancer therapy Provenge continued to grow in the fourth quarter. Seattle-based Dendreon said sales of Provenge rose to ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Since its launch in 2010, investors have been waiting for Dendreon's ($DNDN) prostate cancer vaccine Provenge to get some traction in the U.S. market. But instead of ...